Chronic cough, a prevalent and often vexing condition, poses significant diagnostic and therapeutic challenges for clinicians. This article aims to provide a comprehensive approach to diagnosing and managing chronic cough, with a focus on evidence-based practices and recent advances in the field.
Diagnosing chronic cough requires a systematic approach that involves a thorough patient history and physical examination. The clinician should consider common causes such as gastroesophageal reflux disease (GERD), asthma, and upper airway cough syndrome (UACS). However, less common etiologies like bronchogenic carcinoma or foreign body aspiration must also be considered. Diagnostic tools such as chest X-rays, spirometry, and bronchoscopy can facilitate the identification of the underlying cause.
Management of chronic cough should be tailored to the identified cause. For example, GERD-related cough may respond to proton pump inhibitors, while inhaled corticosteroids may be beneficial for cough variant asthma. For idiopathic chronic cough, recent studies suggest that speech therapy may be an effective intervention. It is also essential to reassess and adjust the treatment plan regularly based on the patient's response.
Recent advancements have led to the identification of novel cough biomarkers and the development of new antitussive drugs. For instance, P2X3 antagonists have shown promising results in clinical trials for refractory chronic cough. Additionally, the role of cough hypersensitivity syndrome in chronic cough is gaining recognition, opening new avenues for therapeutic interventions.
Chronic cough is a complex clinical entity that requires a comprehensive and individualized approach to diagnosis and management. Understanding the common and uncommon causes, employing a systematic diagnostic approach, and staying abreast of emerging trends can help clinicians effectively manage this challenging condition. Continuous research and innovation in this field promise to bring new insights and improved patient outcomes in the future.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation